Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone

Leuk Lymphoma. 2009 Jul;50(7):1217-8. doi: 10.1080/10428190902912486.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use*
  • Arsenic Trioxide
  • Arsenicals / therapeutic use
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Leukemia, Promyelocytic, Acute / chemically induced*
  • Leukemia, Promyelocytic, Acute / complications*
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Male
  • Mitoxantrone / adverse effects*
  • Multiple Sclerosis / complications
  • Multiple Sclerosis / drug therapy*
  • Oxides / therapeutic use
  • Remission Induction
  • Topoisomerase II Inhibitors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Arsenicals
  • Enzyme Inhibitors
  • Oxides
  • Topoisomerase II Inhibitors
  • Mitoxantrone
  • Arsenic Trioxide